[aidsnews] AIDS Treatment News Daily Alerts - sample email
John S James
looks like, if you choose to subscribe by email instead of visiting
the site. You can subscribe at the same site, http://
aidsnews.blogspot.com, to get a similar email almost every day.
You can click the underlined titles for more information on each
story. But for now there is an extra step with email, since the first
click just gets you to the same story on the blog, then you need to
click the title again to get to the original article. We are trying
to fix this glitch.
It may be easier to just visit the blogspot site, above, when you
want to read the news; then one click will get you to the original
article. Our site is free, ad-free, and registration-free.
John
AIDS Treatment News - daily alerts
The curiosity of IL-15
Posted: 06 Aug 2007 03:11 PM CDT
"Mice deficient for the cytokine interleukin-15 are unexpectedly
protected from sepsis. Orinska and colleagues show that
interleukin-15 signals intracellularly in mast cells and limits their
recruitment of neutrophils to clear the infection."
There is considerable interest in the role of IL-15 in HIV.
[Original technical article available to subscribers to Nature.]
Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV,
Approved by FDA
Posted: 06 Aug 2007 02:57 PM CDT
Maraviroc (now spelled Selzentry, not Celsentri) approved by FDA;
first approved drug in new class of CCR5 inhibitors.
Monogram Biosciences (MGRM) Lauches Trofile Co-Receptor Tropism Assay
Posted: 06 Aug 2007 02:40 PM CDT
This test is used to see if a patient's HIV uses the CCR5 co-receptor
for entry. If so, the newly approved miraviroc (Selzentry) may be an
appropriate antiretroviral.
Libya: Medics Dispute Still Haunts Libya
Posted: 06 Aug 2007 02:21 PM CDT
A detailed history of the notorious case appeared today in This Day
newspaper, Lagos, Nigeria.
Publix to offer 7 popular prescription antibiotics for free
Posted: 06 Aug 2007 12:08 PM CDT
This new step in commercial access shows what can be done with a good
business model. The drugs are cheap and the publicity is invaluable.
Of course this model won't scale up very far; the next company to do
it won't get the same attention. But still it illustrates the
strategy of finding a better model, instead of forcing a bad one on
people.
India: Chennai court rejects Novartis patent challenge
Posted: 06 Aug 2007 11:36 AM CDT
Novartis said it is unlikely to appeal.
Salome’s Secret
Posted: 06 Aug 2007 11:59 AM CDT
It has been known for some time that certain prostitutes did not get
HIV despite thousands of exposures -- yet they were not immune, as
they could get HIV later after they retired from sex work but were
exposed to the virus again. An article in POZ shows that this finding
is not just a curiosity, but a key opportunity for research toward
developing future microbicides (and possibly treatments as well).
The POZ story also illustrates the "rhetoric of HIV, rhetoric of
silence around it, the rhetoric of stigma” as a field of study and
action.
Zimbabwe: Government Now Providing Free ARVs
Posted: 06 Aug 2007 07:55 AM CDT
"The Government is now providing free anti-retroviral drugs to people
on the public ARV programme after waiving payment of a nominal fee"
HIV and Hepatitis.com publishes many reports from the IAS Conference
in Sydney, for example:
Posted: 05 Aug 2007 05:03 PM CDT
* Efficacy and Safety of Etravirine (TMC125) in Treatment-experienced
HIV Patients: 24-week Results from the DUET-1 and DUET-2 Trials -
8/03/07
* Once-daily Ritonavir-boosted Fosamprenavir (Lexiva) or Atazanavir
(Reyataz), Both with Tenofovir/emtricitabine in Treatment-naive
Patients: 48-week Results of the ALERT Trial - 8/03/07
* Experimental Integrase Inhibitor Elvitegravir Has Additive to
Synergistic Interactions with Other Antiretrovirals in vitro and No
Relevant PK Drug Interaction with Darunavir/ritonavir or Tipranavir/
ritonavir - 8/03/07
* "Lipodystrophy" Is Not What It Used to Be: Data from the Swiss HIV
Cohort Study - 8/03/07
* Effects of Tipranavir/ritonavir Compared to Lopinavir/ritonavir on
Changes in Body Composition and Metabolic Parameters in Treatment-
naÔve Patients - 8/03/07
* Switching to Truvada More Effective than Epzicom Due to Abacavir
Hypersensitivity - 7/31/07
* Emtricitabine/tenofovir (Truvada) versus Zidovudine/lamivudine
(Combivir), Both in Combination with Efavirenz (Sustiva): 3-year Data
- 7/31/07
* Experimental CCR5 Antagonist INCB009471 Shows Sustained Anti-HIV
Activity in Early Clinical Trial - 7/31/07
* Risk of Skin Cancer Elevated in People with HIV - 7/31/07
* PrEP and Timed Intercourse for Conception in Serodiscordant Couples
- 7/31/07
* Methamphetamine Use Associated with Lower CD4 Cell Counts in People
with HIV - 7/31/07
* CCR5 Antagonist Maraviroc (Celsentri) Not Quite as Effective as
Efavirenz but Better Tolerated in Treatment-naive Patients - 7/27/07
* Experimental Integrase Inhibitor Raltegravir Achieves HIV Viral
Load Reductions Comparable to Sustiva and Shows a More Favorable
Lipid and Tolerability Profile in Treatment-naÔve Patients - 7/27/07
* 48-week Efficacy and Safety of Darunavir (Prezista) Boosted with
Ritonavir versus Lopinavir/ritonavir (Kaletra) in Treatment-
experienced HIV Patients: The TITAN Trial - 7/27/07
* Safety and Efficacy of Experimental CCR5 Antagonist Vicriviroc in
Treatment-experienced HIV Patients: 48 week Results of ACTG 5211 -
7/27/07
* Treating HIV-Infected Infants Early Helps Them Live Longer - 7/27/07
* HLA-B*5701 Genetic Testing Effectively Predicts Which Patients Are
at Risk for Abacavir (Ziagen) Hypersensitivity Reactions - 7/27/07
* Impact on Efficacy and Lipid Profiles of Saquinavir/ritonavir
(Invirase) vs Lopinavir/ritonavir (Kaletra): The Gemini Study at 24
Weeks - 7/24/07
* Experts Disagree about Prospects for HIV Cure - 7/24/07
* Lopinavir/ritonavir (Kaletra) Monotherapy Suppresses HIV Viral Load
in HIV-1-treatment-naÔve Patients: 48-week Results of IMANI-2 - 7/24/07
* New Maturation Inhibitor May Be More Potent than Bevirimat (PA-457)
- 7/24/07
The Role of State Pharmaceutical Assistance Programs in Serving Low-
Income Medicare Beneficiaries Following the Implentation of Medicare
Part D
Posted: 05 Aug 2007 04:30 PM CDT
This 15-page detailed report could help you if you are on the
Medicare Part D drug benefit. Download the "issue brief" on this page.
Metabolic Complications in HIV-Infected Patients
Posted: 05 Aug 2007 04:16 PM CDT
This program offers continuing medical education credit for
physicians -- but anyone can use it (free registration required on
the site).
"Learning Objectives
"Upon completion of this activity, participants should be able to:
* Explain the epidemiology of cardiovascular risk factors in HIV-
infected patients
* Discuss the associations between specific antiretroviral agents and
metabolic complications and the implications of these data for
treatment strategies
* Describe approaches to the management of hyperlipidemia, insulin
resistance, and body fat perturbations in HIV-infected patients"
--
John S James
AIDS Treatment News
www.aidsnews.org
[Non-text portions of this message have been removed]
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/aidsnews/
<*> Your email settings:
Individual Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/aidsnews/join
(Yahoo! ID required)
<*> To change settings via email:
mailto:aidsnew...@yahoogroups.com
mailto:aidsnews-f...@yahoogroups.com
<*> To unsubscribe from this group, send an email to:
aidsnews-u...@yahoogroups.com
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
***********************************************************
For AIDS/HIV+ resources, visit the s.s.a.h+ website at :
http://www.webcom.com/benny/ssah/ssah+.html
***********************************************************